The GD40h is a combined glucose and I-ketone meter for Type I & II diabetics
Suitable for Type I & II diabetics
0-70% haematocrit range, largest range on the market
Exceeds EN ISO 15197:2015
Large, back lit display
Voice results for impaired hearing users (Universal tone technology)
Auto strip ejection
Suitable for neonatal, children, gestational and dialysis patients
0.5mcl sample and 5 second result
Compatible with Diasend
Free APP for Apple and Android, results automatically downloaded via Bluetooth
Two kinds of communication export, Wired and Bluetooth
Free meters, controls, batteries
Free training for clinical staff and patients
Free Surgery patient reviews
Connect other separate devices such as weight and BMI using the FORA W550 digital scales and BP results using the FORA P30 digital monitor
1. INTENDED USE FIV Ab + FeLV Ag Combined Rapid Test is a combined cassette to differentially diagnose the presence of Feline Immunodeficiency antibody and Feline Leukemia Virus antigen in cat's blood. Assay Time: 10-15 min Sample: serum, plasma or whole blood 2. PRINCIPLE OF THE ASSAY FIV Ab + FeLV Ag Combined Rapid Test is based on sandwich lateral flow immunochromatographic assay. The test device has two testing windows. Each testing window has an invisible T (test) zone and C (control) zone. When sample is applied into the sample hole on the device, the liquid will laterally flow on the surface of the test strip. If there is enough FIV antibody or FeLV antigen in the sample, a visible T band will appear in the corresponding testing window. The C band should always appear after a sample is applied, indicating a valid result. By this means, the device can accurately indicate the presence of FIV antibody or FeLV antigen in the sample. 3. KIT COMPONENT - 10 foil pouches, each containing a cassette,pipette and desiccant - 10 assay buffer tubes (0.5 mL each) - 10 centrifugal tubes - Product Manual
1. INTENDED USE CDV + CPV Ag Combined Rapid Test is a combined cassette to diagnose the presence of Canine Disteimper virus antigen and Canine Parvovirus antigen in dogâ??s secretions, serum or feces. Assay Time: 5 - 10 min Sample: Secretions, serum or feces 2. PRINCIPLE OF THE ASSAY CDV + CPV Ag Combined Rapid Test is based on sandwich lateral flow immunochromatographic assay. The test device has two testing windows. Each testing window has an invisible T (test) zone and C (control) zone. When sample is applied into the sample hole on the device, the liquid will laterally flow on the surface of the test strip. If there is enough CDV antigen or CPV antigen in the sample, a visible T band will appear in the corresponding testing window. The C band should always appear after a sample is applied, indicating a valid result. By this means, the device can accurately indicate the presence of CDV antigen or CPV antigen in the sample. 3. KIT COMPONENT - 10Ã?foil pouches each containing a cassette, pipette and desiccant - 10Ã?assay buffer tubes (0.7 mL each) - 10Ã?assay buffer tubes (1.0 mL each) - 20Ã?swab sticks - Product Manual
Anti-SARS-CoV-2 Rapid Test, COVID-19 1. Easier: No special equipment needed, Intuitive visual interpretation. 2. Rapid: Quick sampling by fingertip blood, Results in 10-15min. 3. Accurate: Results with IgG and IgM respectively. 4. Application: as screening tool for potential suspect patients in large numbers. Testing kit is FDA Emergency Use Authorization (EUA) Approved Testing kit is CE MARKED-IVD * Instruction for Use * Interpretation Guide * SARS-CoV-2 immunoassays * Accuracy of the Anti-SARS-CoV-2 Rapid Test Kit * Anti-SARS Rapid Test Brochure * COVID-19 Catalog * EUA Approval Letter * Fact Sheet for Healthcare Providers * FDA Letter * Fact Sheet for Recipients * FAQ * CE IVD Notification Certificate Antibody Performance Measure Estimate of Performance 95% Confidence Interval IgM Sensitivity (PPA) 95.7% (289/302) (92.8%; 97.5%) IgM Specificity (NPA) 99.7% (311/312) (98.2%; 99.9%) IgG Sensitivity (PPA) 99.0% (299/302) (97.1%; 99.7%) IgG Specificity (NPA) 99.4% (310/312) (97.7%; 99.8%) Combined Sensitivity (PPA) 99.0% (299/302) (97.1%; 99.7%) Combined Specificity (NPA) 99% (309/312) (97.2%; 99.7%) Combined PPV at prevalence = 5% 84.4% (64.6%; 94.6%) Combined NPV at prevalence = 5% 99.9% (99.8%; 100%) Testing kit is FDA Emergency Use Authorization (EUA) Approved Testing kit is CE MARKED-IVD * Instruction for Use * Interpretation Guide * SARS-CoV-2 immunoassays * Accuracy of the Anti-SARS-CoV-2 Rapid Test Kit * Anti-SARS Rapid Test Brochure * COVID-19 Catalog * EUA Approval Letter * Fact Sheet for Healthcare Providers * FDA Letter * Fact Sheet for Recipients * FAQ * CE IVD Notification Certificate
1. INTENDED USE CPV + CCV Ag Combined Test is a combined cassette to differentially diagnose the presence of Canine Parvovirus antigen and Canine Coronavirus antigen in dogâ??s feces or vomit. Assay Time: 5 -10 min Sample: Feces or vomit 2. PRINCIPLE OF THE ASSAY CPV + CCV Ag Combined Test is based on sandwich lateral flow immunochromatographic assay. The test device has two testing windows. Each testing window has an invisible T (test) zone and C (control) zone. When sample is applied into the sample hole on the device, the liquid will laterally flow on the surface of the test strip. If there is enough CPV antigen or CCV antigen in the sample, a visible T band will appear in the corresponding testing window. The C band should always appear after a sample is applied, indicating a valid result. By this means, the device can accurately indicate the presence of CPV antigen or CCV antigen in the sample. 3. KIT COMPONENT - 10Ã?foil pouches, each containing acassette, pipette and desiccant - 10Ã?assay buffer tubes (1.0 mL each) - 10Ã?swab sticks - Product Manual
General information One-step cdv + cpv ag combined rapid test is a combined cassette to diagnose the presence of canine disteimper virus antigen and canine parvovirus antigen in dog’s secretions, serum or feces. Sensitivity : cdv 100% cpv 99.3% Specificity :cdv 99.8% cpv 99.4% Specimen: secretions, serum or feces Reading timen:5-10 min
1. INTENDED USE CPV + CCV +Giardia Ag Triple Test is a combined cassette to differentially diagnose the presence of Canine Parvovirus antigen, Canine Coronavirus antigen and Giardia antigen in dogâ??s feces or vomit. Assay Time: 5-10 min Sample: Feces or vomit 2. PRINCIPLE OF THE ASSAY CPV + CCV + Giardia Ag Triple Test is based on sandwich lateral flow immunochromatographic assay. The test device has three testing windows. Each testing window has an invisible T (test) zone and C (control) zone. When sample is applied into the sample hole on the device, the liquid will laterally flow on the surface of the test strip. If there is enough CPV antigen, CCV antigen or Giardia antigen in the sample, a visible T band will appear in the corresponding testing window. The C band should always appear after a sample is applied, indicating a valid result. By this means, the device can accurately indicate the presence of CPV, CCV or Giardia antigen in the sample. 3. KIT COMPONENT - 10Ã?foil pouches, each containing onecassette and a desiccant - 10Ã?assay buffer tubes (1.0 mL each) - 10Ã?pipettes - 10Ã?swab sticks - Product Manual
After the virus infection, the antibody IgM appears and rises in the early stage, while antibody IgG appears and rises in the late stage. â?¢ By combining IgG and IgM, we can know if the body is infected and at which stage . the Kit inckude: Novel Coronavirus (2019-nCoV) IgG/IgM Test Kit (Colloidal Gold) â?¢ Transport or store at room temperature from 2 to 30°C â?¢ If individual pouch unopened, the kit can be stored for 12 months. â?¢ Once the individual pouch is opened, this test card should be used within 1 hour.
The Herpes Simplex Virus Rapid Test is a rapid qualitative lateral flow test designed for the quantitive detection of IgG antibodies to Herpes Simplex Virus (HSV) in human serum/plasma samples. HSV-1 is usually associated with infection in oropharyngeal area and eyes, while HSV-2 causes mostly genital and neonatal infections (5, 6), however, the tissue specificity is not absolute (7). HSV-2 can be isolated occasionally from the oropharynx and 5-10% of primary genital infections may be caused by HSV-1. Infants infected with HSV appear normal at birth, but almost invariably develop symptoms during the newborn period (5, 8, 9). Neonatal HSV infection may remain localized or become disseminated. Localized infection may involve one or a combination of sites. These are skin, eyes, mouth or the central nervous system. Disseminated infection is manifested by pneumonitis, hepatitis, disseminated intravascular coagulopathy and encephalitis. Of the infants with neonatal HSV, about one half of those surviving will develop severe neurological or ocular sequelae. A number of serological procedures have been developed to detect antibodies to HSV. These include complement fixation, indirect immunofluorescent antibody, plaque neutralization, and ELISA (6, 8, 10). Antibody of the IgG class is produced during the first 2-3 weeks of infection with HSV and exists only transiently in most patients. Serologic procedures, which measure the presence of IgG antibodies, help discriminate between primary and recurrent infections, since IgG antibodies is rarely found in recurrent infections. High affinity IgG antibodies to HSV, if present in a sample, may interfere with the detection of IgG specific antibody (9). High affinity IgG antibody may preferentially bind to HSV-1 antigen leading to false negative IgG results. Also, rheumatoid factor, if present, along with antigen specific IgG, may bind to IgG causing false positive IgG results. Both problems can be eliminated by deactivating IgG in the sample before testing for IgG.
PANODYNE - The new rapid lgM-lgG combined antibody test* for COVID-19 from Multibrands International is now available to test for the detection of lgG and lgM antibodies of coronavirus from a small specimen of human serum, plasma or whole blood. The detection works with proteins to indicate if a person's immune system has responded with the COVID-19 virus to indicate infection.